Ben R. Taylor - 16 Jun 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Financial Officer
Signature: /s/ Kyle Nelson, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 16 Jun 2025
Net transactions value: -$34,720
Form type: 4
Filing time: 18 Jun 2025, 16:32:45 UTC
Previous filing: 19 May 2025
Next filing: 19 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Taylor Ben R	Chief Financial Officer	41 S. RIO GRANDE STREET, SALT LAKE CITY	/s/ Kyle Nelson, attorney-in-fact	18 Jun 2025	0001712276

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Tax liability	$34,720	-7,057	-0.85%	$4.92	823,134	16 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	RXRX	Stock Option (Right to Buy)						70,037	16 Jun 2025	Class A Common Stock	0	$7.25	Direct	F2
holding	RXRX	Stock Option (Right to Buy)						740,686	16 Jun 2025	Class A Common Stock	0	$6.09	Direct	F3
holding	RXRX	Stock Option (Right to Buy)						81,154	16 Jun 2025	Class A Common Stock	0	$0.1400	Direct	F4
holding	RXRX	Stock Option (Right to Buy)						92,748	16 Jun 2025	Class A Common Stock	0	$0.0600	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						289,837	16 Jun 2025	Class A Common Stock	0	$0.0400	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F3	1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date.
F4	Twenty-five percent of the shares subject to the award vest and become exercisable on July 1, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
F5	Twenty-five percent of the shares subject to the award vest and become exercisable on April 3, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
F6	Twenty-five percent of the shares subject to the award vest and become exercisable on November 17, 2021, and the remaining shares subject to the award vest and become exercisable in annual installments thereafter, subject to Mr. Taylor's continued service through each vesting date.